AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Orthostatic Hypotension: Midodrine works by constricting blood vessels, which helps to increase blood pressure. This effect can alleviate symptoms such as dizziness, lightheadedness, and fainting that occur when blood pressure drops upon standing. Orthostatic hypotension can be caused by various conditions, including neurological disorders, autonomic nervous system dysfunction, dehydration, and certain medications.
Improved Upright Tolerance: By raising blood pressure, midodrine can improve the ability of individuals with orthostatic hypotension to tolerate being in an upright position, such as standing or sitting. This can enhance their overall quality of life by reducing symptoms and enabling them to engage in daily activities more comfortably.
Dosage and Administration: Midodrine hydrochloride is typically taken orally, with doses adjusted based on individual patient response and tolerability. It is usually recommended to take the medication in the morning and early afternoon to minimize the risk of supine hypertension (high blood pressure while lying down). The dosage regimen should be determined by a healthcare professional familiar with the management of orthostatic hypotension.
Potential Side Effects: Like any medication, midodrine hydrochloride can cause side effects. Common side effects may include scalp tingling, goosebumps, itching, urinary retention, and supine hypertension. Supine hypertension refers to elevated blood pressure while lying down, which can increase the risk of cardiovascular complications. Monitoring blood pressure regularly and adjusting the dosage as needed can help mitigate this risk.
Contraindications: Midodrine hydrochloride is contraindicated in patients with severe organic heart disease, acute renal disease, urinary retention, pheochromocytoma (a type of adrenal gland tumor), and thyrotoxicosis (overactive thyroid). It should also be used with caution in patients with impaired renal function, as dosage adjustments may be necessary to prevent accumulation of the drug.
Special Populations: Midodrine hydrochloride should be used with caution in elderly patients, as they may be more susceptible to adverse effects such as supine hypertension. Additionally, its safety and efficacy have not been established in pediatric patients.
Interactions: Midodrine hydrochloride may interact with other medications, particularly those that affect blood pressure or cardiac function. It is important for patients to inform their healthcare provider about all medications, supplements, and herbal products they are taking to avoid potential interactions.
Rank | Probiotic | Impact |
---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
Taxonomy | Rank | Effect | Citations | Notation |
---|---|---|---|---|
Segatella | genus | Decreases | 👪 Source Study | |
Eggerthella | genus | Decreases | 👪 Source Study | |
Streptococcus | genus | Decreases | 👪 Source Study | |
Lacrimispora | genus | Decreases | 👪 Source Study | |
Odoribacter | genus | Decreases | 👪 Source Study | |
Roseburia | genus | Decreases | 👪 Source Study | |
Bacteroides | genus | Decreases | 👪 Source Study | |
Ruminococcus | genus | Decreases | 👪 Source Study | |
Segatella copri | species | Decreases | 📓 Source Study | Over 70%ile Indicator of mycotoxin present |
Eggerthella lenta | species | Decreases | 📓 Source Study | |
Streptococcus parasanguinis | species | Decreases | 📓 Source Study | |
Lacrimispora saccharolytica | species | Decreases | 📓 Source Study | |
Odoribacter splanchnicus | species | Decreases | 📓 Source Study | |
Roseburia hominis | species | Decreases | 📓 Source Study | |
Bacteroides fragilis | species | Decreases | 📓 Source Study | H02076 Bacteroides infection |
Ruminococcus bromii | species | Decreases | 📓 Source Study |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0.2 | 0.2 | 0 |
Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | |
Allergic Rhinitis (Hay Fever) | 0 | 0 | |
Allergies | 0.3 | 0.6 | -1 |
Allergy to milk products | 0 | 0 | |
Alzheimer's disease | 0.1 | 0.3 | -2 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.2 | 0 | 0 |
Ankylosing spondylitis | 0.7 | 0 | 0 |
Anorexia Nervosa | 0.1 | -0.1 | |
Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
Asthma | 0.4 | 0.1 | 3 |
Atherosclerosis | 0 | 0.4 | 0 |
Atrial fibrillation | 0.2 | 0.6 | -2 |
Autism | 1.4 | 0.9 | 0.56 |
Barrett esophagus cancer | 0.2 | -0.2 | |
Biofilm | 0.3 | 0.3 | |
Bipolar Disorder | 0 | 0.3 | 0 |
Brain Trauma | 0.1 | -0.1 | |
Cancer (General) | 0.1 | 0.1 | |
Carcinoma | 0.6 | 0.2 | 2 |
Celiac Disease | 0.3 | 0.2 | 0.5 |
Cerebral Palsy | 0.2 | 0.1 | 1 |
Chronic Fatigue Syndrome | 0.8 | 0.5 | 0.6 |
Chronic Kidney Disease | 0.2 | 0.1 | 1 |
Chronic Lyme | 0.1 | -0.1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.5 | 0.1 | 4 |
Chronic Urticaria (Hives) | 0.2 | 0.6 | -2 |
Coagulation / Micro clot triggering bacteria | 0.2 | 0.2 | 0 |
Colorectal Cancer | 0.3 | 0.3 | |
Constipation | 0 | 0.1 | 0 |
Coronary artery disease | 0 | 0 | |
COVID-19 | 1 | 1.3 | -0.3 |
Crohn's Disease | 0.5 | 0.3 | 0.67 |
cystic fibrosis | 0.1 | -0.1 | |
deep vein thrombosis | 0.2 | -0.2 | |
Depression | 1.4 | 0.3 | 3.67 |
Dermatomyositis | 0.2 | 0.2 | |
Eczema | 0.2 | -0.2 | |
Endometriosis | 0.2 | 0.2 | 0 |
Epilepsy | 0.2 | 0 | 0 |
Fibromyalgia | 0.1 | 0.6 | -5 |
Functional constipation / chronic idiopathic constipation | 0.1 | 0.7 | -6 |
gallstone disease (gsd) | 0 | 0.1 | 0 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0 | 0.2 | 0 |
Generalized anxiety disorder | 0 | 0 | |
Glioblastoma | 0.2 | -0.2 | |
Graves' disease | 0 | 0.1 | 0 |
Halitosis | 0 | 0.2 | 0 |
Hashimoto's thyroiditis | 0.1 | 0 | 0 |
Hidradenitis Suppurativa | 0.2 | 0.2 | |
High Histamine/low DAO | 0.1 | 0 | 0 |
hypercholesterolemia (High Cholesterol) | 0.1 | 0.1 | |
hyperglycemia | 0 | 0 | |
hypertension (High Blood Pressure | 0.2 | 0.6 | -2 |
Hypothyroidism | 0.2 | -0.2 | |
Hypoxia | 0 | 0 | |
IgA nephropathy (IgAN) | 0.6 | -0.6 | |
Inflammatory Bowel Disease | 0.4 | 0.7 | -0.75 |
Insomnia | 0.2 | 0.1 | 1 |
Intelligence | 0.6 | -0.6 | |
Intracranial aneurysms | 0 | 0 | |
Irritable Bowel Syndrome | 0.1 | 0.1 | 0 |
Liver Cirrhosis | 0.4 | 0.3 | 0.33 |
Long COVID | 0.5 | 0.3 | 0.67 |
Low bone mineral density | 0.1 | -0.1 | |
Lung Cancer | 0 | 0 | |
Mast Cell Issues / mastitis | 0.2 | 0 | 0 |
ME/CFS with IBS | 0.2 | 0 | 0 |
ME/CFS without IBS | 0.8 | 0 | 0 |
Metabolic Syndrome | 0.7 | 0.6 | 0.17 |
Mood Disorders | 1.4 | 0.5 | 1.8 |
multiple chemical sensitivity [MCS] | 0.2 | 0.2 | |
Multiple Sclerosis | 1.1 | 0.9 | 0.22 |
Multiple system atrophy (MSA) | 0.5 | 0 | 0 |
neuropathic pain | 0.2 | -0.2 | |
Neuropathy (all types) | 0.2 | 0.2 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.7 | 0.2 | 2.5 |
NonCeliac Gluten Sensitivity | 0.2 | 0 | 0 |
Obesity | 0.7 | 0.2 | 2.5 |
obsessive-compulsive disorder | 0.2 | 0.7 | -2.5 |
Osteoarthritis | 0.2 | 0 | 0 |
Osteoporosis | 0.2 | 0 | 0 |
pancreatic cancer | 0.3 | 0.3 | |
Parkinson's Disease | 0.4 | 1.2 | -2 |
Polycystic ovary syndrome | 0 | 0.2 | 0 |
Psoriasis | 0.2 | 0.7 | -2.5 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1 | 0.3 | 2.33 |
Rosacea | 0 | 0.1 | 0 |
Schizophrenia | 0.4 | 0.1 | 3 |
scoliosis | 0 | 0 | |
Sjögren syndrome | 0.9 | 0 | 0 |
Sleep Apnea | 0 | 0.3 | 0 |
Slow gastric motility / Gastroparesis | 0 | 0 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0.2 | |
Stress / posttraumatic stress disorder | 0.1 | 0.5 | -4 |
Systemic Lupus Erythematosus | 0.6 | 0.2 | 2 |
Tic Disorder | 0.2 | 0.6 | -2 |
Tourette syndrome | 0 | 0 | |
Type 1 Diabetes | 0.1 | 0.2 | -1 |
Type 2 Diabetes | 0.7 | 0.3 | 1.33 |
Ulcerative colitis | 0.2 | 0.8 | -3 |
Unhealthy Ageing | 0.4 | 0.2 | 1 |
Vitiligo | 0.2 | 0.2 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [98.80.143 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [98.80.143 ]